Comparing laparoscopic and open ablation for liver tumors
Laparoscopic Versus Open Ablation of Liver Malignancies: a Randomized, Controlled Multicenter Trial
NA · Rigshospitalet, Denmark · NCT06304766
This study is testing whether laparoscopic surgery is safer and more effective than open surgery for people with liver tumors.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Rigshospitalet, Denmark (other) |
| Locations | 1 site (Copenhagen) |
| Trial ID | NCT06304766 on ClinicalTrials.gov |
What this trial studies
This study compares laparoscopic ablation to open ablation for liver malignancies, focusing on complication rates, ablation response, and quality of life post-surgery. Liver malignancies are a significant cause of cancer-related deaths, and this research aims to provide insights into less invasive treatment options. By evaluating the effectiveness and safety of these two surgical approaches, the study seeks to identify which method offers better outcomes for patients with tumors unsuitable for percutaneous ablation.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with primary liver cancer or liver metastases that are not suitable for percutaneous ablation.
Not a fit: Patients undergoing ablation in conjunction with resection or those unable to understand or cooperate with the study may not benefit.
Why it matters
Potential benefit: If successful, this study could lead to safer surgical options with fewer complications for patients with liver malignancies.
How similar studies have performed: Previous studies have indicated that laparoscopic techniques can reduce complication rates compared to open surgery, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * One or more tumors not amenable to percutaneous ablation, age ≥ 18, signed informed consent, diagnosis of primary liver cancer or liver metastases from any primary tumor, and tumor suitable for ablation as primary treatment. Exclusion Criteria: * Ablation performed in conjunction with resection, patients who cannot cooperate with the study, and patients who do not understand or speak Danish.
Where this trial is running
Copenhagen
- Rigshospitalet — Copenhagen, Denmark (RECRUITING)
Study contacts
- Principal investigator: Hans-Christian Pommergaard, MD DMSc PhD — Rigshospitalet, Denmark
- Study coordinator: Lucas Alexander Knøfler, MD
- Email: lucas.alexander.knoefler@regionh.dk
- Phone: +4520114529
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Hepatocellular Carcinoma, Cholangiocarcinoma, Liver Metastases, Laparoscopic ablation, Open ablation, Complications, Ablation response, Quality of life